Crucial knowledge gaps hinder our ability to treat nicotine dependence optimally. We know too little about the relative efficacies of pharmacotherapies in both clinical trials and real-world contexts. We know too little about how to deliver treatment: e.g., how to match patients with pharmacotherapies, how to incorporate treatment seamlessly into health care delivery systems and how to combine pharmacotherapies. In addition, we know too little about the global, long-term consequences of quit attempts: e.g., the downstream physiological, psychosocial, and health care utilization effects of continuing to smoke versus successfully quitting. Finally, we lack understanding of the mechanisms by which treatments work. These gaps will be addressed via four research projects and supportive cores. The first project (N=1520) will contrast efficacies of five different pharmacotherapies and a placebo, explore their mechanisms of action and yield algorithms for their optimal use. The second project will follow from the first project participants for at least 3 years and capture the diverse physical and psychosocial health outcomes of a quit attempt. The third project (N=1320) will study the active pharmacotherapies used in the first project, but in an effectiveness, primary care context. Data will address treatment utilization, success, and validate treatment algorithms. The fourth project will track from the third project subjects along with anonymous controls and reveal the impact of cessation on health care utilization and costs within a large network of primary care clinics. In addition, the UW-TTURC proposal includes an Administrative Core providing shared resources and infrastructure, a Career Development Core to increase the number of clinician-scientists entering the field of tobacco control research, and a Developmental Research Core to support innovative tobacco control research. The proposed work will advance the understanding and effectiveness of tobacco dependence treatment through integrated transdisciplinary research and result in more smokers quitting successfully.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
3P50DA019706-07S1
Application #
7244661
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Denisco, Richard A
Project Start
1999-09-30
Project End
2009-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
7
Fiscal Year
2006
Total Cost
$130,471
Indirect Cost
Name
University of Wisconsin Madison
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Guerreiro, Rita; Ross, Owen A; Kun-Rodrigues, Celia et al. (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 17:64-74
Allen, Alicia M; Carlson, Samantha; Eberly, Lynn E et al. (2018) Use of hormonal contraceptives and smoking cessation: A preliminary report. Addict Behav 76:236-242
Deng, Sien; E McCarthy, Danielle; E Piper, Megan et al. (2018) Extreme Response Style and the Measurement of Intra-Individual Variability in Affect. Multivariate Behav Res 53:199-218
Burgess-Hull, Albert J; Roberts, Linda J; Piper, Megan E et al. (2018) The social networks of smokers attempting to quit: An empirically derived and validated classification. Psychol Addict Behav 32:64-75
Glasheen, Cristie; Johnson, Eric O; Saccone, Nancy L et al. (2018) Is the Fagerström test for nicotine dependence invariant across secular trends in smoking? A question for cross-birth cohort analysis of nicotine dependence. Drug Alcohol Depend 185:127-132
Teitelbaum, A M; Murphy, S E; Akk, G et al. (2018) Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. Pharmacogenomics J 18:136-143
Hancock, D B; Guo, Y; Reginsson, G W et al. (2018) Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. Mol Psychiatry 23:1-9
Singh, Tarjinder; Walters, James T R; Johnstone, Mandy et al. (2017) The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 49:1167-1173
Peckham-Gregory, Erin C; Chakraborty, Rikhia; Scheurer, Michael E et al. (2017) A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood 130:2229-2232
Piper, Megan E; Vasilenko, Sara A; Cook, Jessica W et al. (2017) What a difference a day makes: differences in initial abstinence response during a smoking cessation attempt. Addiction 112:330-339

Showing the most recent 10 out of 120 publications